We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PF4 Immunoassays Investigated in Vaccine-Induced Thrombotic Thrombocytopenia

By LabMedica International staff writers
Posted on 07 Jun 2021
Print article
Image: The AcuStar Hemostasis Testing System (Photo courtesy of Werfen)
Image: The AcuStar Hemostasis Testing System (Photo courtesy of Werfen)
Post-vaccination embolic and thrombotic events, also termed vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or vaccine-induced immune thrombotic thrombocytopenia (VITT) are rare types of blood clotting events that were initially observed in a very small number of people who had previously received the COVID-19 vaccine.

Platelet factor 4 (PF4) is a small cytokine belonging to the CXC chemokine family that is also known as chemokine (C-X-C motif) ligand 4 (CXCL4). This chemokine is released from alpha-granules of activated platelets during platelet aggregation, and promotes blood coagulation by moderating the effects of heparin-like molecules. Due to these roles, it is predicted to play a role in wound repair and inflammation.

Medical Scientists at the Toulouse University Hospital (Toulouse, France) and their colleagues analyzed plasma samples from nine patients (median age, 44 years; seven females, two males) with suspected VITT after vaccination with ChAdOx1 nCoV-19 (AstraZeneca, Cambridge, UK). The most common events were cerebral vein thrombosis (n = 6) and splanchnic vein thrombosis (n = 5). All the patients had severe thrombocytopenia (median platelet count nadir, 29,000/mm3; range, 9 to 61,000) except for one woman with both cerebral vein thrombosis and splanchnic vein thrombosis.

Two rapid immunoassays widely used for the diagnosis of heparin-induced thrombocytopenia, STic Expert HIT (Stago Diagnostica, Asnières-sur-Seine, France) and HemosIL AcuStar HIT-IgG (Instrumentation Laboratory, Bedford, MA, USA) were performed on plasma samples to detect PF4-specific antibodies, and the results were negative in all the patients. Two other rapid tests had been performed in some patients by the referring laboratories and were negative, except in one patient, who had an equivocal result.

The team also tested all plasma samples with three different PF4-specific enzyme-linked immunosorbent assays, variable results were obtained. Significant levels of immunoglobulin (Ig)G antibodies to PF4 were detected in seven patients only by the assay that used PF4–poly(vinyl sulfonate) (PVS) complex as the antigenic target. In addition, optical density values were variable and lower than those previously reported with a similar test. The diagnosis of VITT was confirmed by PF4–serotonin release assay in all seven patients with IgG antibodies to PF4–PVS, whereas a standard serotonin release assay was negative in two patients.

The authors concluded that their results provide further support to show that rapid immunoassays should be avoided in the detection of PF4-specific antibodies in patients with suspected VITT. Therefore, the use of a sensitive, quantitative, immunologic test is strongly recommended, because according to the recently proposed algorithm, nonheparin anticoagulants should be preferred when clinically significant levels of anti-PF4 antibodies are detected. The study was published on May 19, 2021 in The New England Journal of Medicine.


Related Links:
Toulouse University Hospital
AstraZeneca
Stago Diagnostica
Instrumentation Laboratory


Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
Automated Nucleic Acid Extractor
eLab
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more